Daily doses of OCA , ranging from 10 to 50 mg , significantly reduced levels of ALP , - glutamyl transpeptidase , and alanine aminotransferase , compared with placebo , in patients with primary biliary cirrhosis who had inadequate responses to ursodeoxycholic acid .